Clinical Trial

Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer

Study acronym: RAMP205
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study will assess the safety and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma (PDAC) who have been previously untreated.
Protocol Amendment History 26 amendments
This ClinicalTrials.gov record has been amended 26 times since 2022-12-19; most recent amendment 2025-08-29.
Status change: Recruiting → Active, Not Recruiting 2025-08-29
Status change: Not Yet Recruiting → Recruiting 2023-01-03
Trial Details
NCT Number NCT05669482
Lead Sponsor Verastem, Inc.
Conditions KRAS Activating Mutation, Metastatic Cancer, Pancreas Cancer, Neoplasms Pancreatic, Malignant Neoplasm of Pancreas
Enrollment 40 participants
Start Date 2023-03-22
Primary Completion 2026-08-31 (estimated)
Study Completion 2027-08-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-02